(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 September 2022 (09.09.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/185120 A1

(51) International Patent Classification:
A61K 31/506 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:
PCT/IB2022/000098

(22) International Filing Date:
04 March 2022 (04.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/157,586 05 March 2021 (05.03.2021) US

(71) Applicant: **NEWAMSTERDAM PHARMA B.V.** [NL/NL]; (dutch Chamber Of Commerce No. 55971946), Gooimeer 2-35, 1411 DC Naarden (NL).

(72) Inventors: **DITMARSCH, Marc**; Newamsterdam Pharma B.V., Gooimeer 2-35, 1411 DC Naarden (NL). **KASTELEIN, Johannes Jacob Pieter**; Newamsterdam Pharma B.V., Gooimeer 2-35, 1411 DC Naarden (NL). **DAVIDSON, Michael Harvey**; Newamsterdam Pharma B.V., Gooimeer 2-35, 1411 DC Naarden (NL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) **Title:** OBICETRAPIB FOR TREATMENT OF DEMENTIAS




FIG. 4C

(57) **Abstract:** Methods are presented for slowing progression of neurodegenerative disease in a subject who has or is at risk of developing a neurodegenerative disease. The methods comprise administering a therapeutically effective amount of obicetrapib or a pharmaceutically acceptable salt thereof to the subject.

WO 2022/185120 A1